Malta - English - Medicines Authority

espl regulatory consulting ltd - mesalazine - modified-release tablet - mesalazine 1600 milligram(s) - antidiarrheals, intestinal antiinflammatory/antiinfective agents

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: methacrylic acid copolymer; purified talc; silicon dioxide; sodium starch glycollate; stearic acid; iron oxide red; carmellose sodium; carnauba wax; magnesium stearate; titanium dioxide; macrogol 6000; triethyl citrate - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.

Ireland - English - HPRA (Health Products Regulatory Authority)

espl regulatory consulting limited - mesalazine - modified-release tablets - 1600 milligram - aminosalicylic acid and similar agents

Israel - English - Ministry of Health

tradis gat ltd - mesalazine - tablets enteric coated - mesalazine 800 mg - mesalazine - mesalazine - ulcerative colitis:-for the treatment of mild to moderate acute exacerbations. -for the maintenance of remission.crohn's disease:-for the treatment of acute episodes.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; methacrylic acid copolymer; hypromellose; purified talc; colloidal anhydrous silica; iron oxide red; povidone; titanium dioxide; triethyl citrate; ammonia; magnesium stearate; pregelatinised maize starch - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: povidone; magnesium stearate; titanium dioxide; hypromellose; colloidal anhydrous silica; triethyl citrate; purified talc; iron oxide red; microcrystalline cellulose; methacrylic acid copolymer; pregelatinised maize starch; ammonia - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mesalazine -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: purified talc; titanium dioxide; microcrystalline cellulose; povidone; methacrylic acid copolymer; iron oxide red; hypromellose; ammonia; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; triethyl citrate - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mesalazine -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; triethyl citrate; titanium dioxide; povidone; pregelatinised maize starch; methacrylic acid copolymer; microcrystalline cellulose; hypromellose; magnesium stearate; iron oxide red; ammonia; purified talc - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis